CLAIMS

1. A vesicular formulation for use in the treatment of inflammatory dermatoses disorders or gout comprising one or more phospholipids and one or more surfactants, in the absence of a pharmaceutically active agent.

2. A vesicular formulation according to Claim 1, for use in the treatment of atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, or acne vulgaris.

3. A vesicular formulation according Claim 1 or 2, in which the formulation is a cream, lotion, ointment, gel, solution, spray, lacquer or film forming solution.

4. A vesicular formulation according to any of Claims 1 to 3, in which the ratio of phospholipid to surfactant is 1:3 to 30:1.

5. A vesicular formulation according to any preceding claim, in which the formulation contains 2.0 to 10.0% by weight phospholipid.

6. A vesicular formulation according to any preceding claim, in which the formulation contains 0.2 to 5.0% by weight surfactant.

7. A vesicular formulation according to any of Claims 1 to 5, in which the formulation contains 0.2% to 0.5% by weight surfactant.

8. A vesicular formulation according to any of Claims 1 to 6, in which the phospholipid is phosphatidylcholine.

9. A vesicular formulation according to any preceding claim, in which the surfactant is a nonionic surfactant selected from the group consisting of: polyoxyethylene sorbitans, polyhydroxyethylene stearates or polyhydroxethylene laurylethers.

10. A vesicular formulation according to any preceding claim, in which the surfactant is polysorbate 80 (Tween 80).

CLAIMS

1. Use of a vesicular formulation comprising one or more phospholipids and one or more non-ionic surfactants in the manufacture of a medicament for the treatment of inflammatory dermatoses disorders or fungal infection, in which the formulation does not comprise any non-lipid, non-surfactant pharmaceutically active agent and in which the medicament is topically applied.

2. Use of a vesicular formulation according to Claim 1, for the treatment of atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, or acne vulgaris.

3. Use of a vesicular formulation according to Claim 1 or 2, in which the formulation is a cream, lotion, ointment, gel, solution, spray, lacquer or film forming solution.

4. Use of a vesicular formulation according to Claim 1, 2 or 3, in which the ratio of phospholipid to surfactant is about 1:3 to about 30:1.

5. Use of a vesicular formulation according to any preceding claim, in which the formulation contains 2.0 to 10.0% by weight phospholipid.

6. Use of a vesicular formulation according to any preceding claim, in which the formulation contains 0.2 to 0.5% by weight surfactant.

7. Use of a vesicular formulation according to any of Claims 1 to 5, in which the formulation contains 0.2% to 0.5% by weight surfactant.

8. Use of a vesicular formulation according to any of Claims 1 to 6, in which the phospholipid is phosphatidylcholine.

9. Use of a vesicular formulation according to any preceding claim, in which the surfactant is a nonionic surfactant selected from the group consisting of: polyoxyethylene sorbitans, polyhydroxyethylene stearates or polyhydroxethylene laurylethers.

10. Use of a vesicular formulation according to any preceding claim, in which the surfactant is polysorbate 80 (Tween 80).